Does beta-blocker therapy reduce mortality in patients with obstructive hypertrophic cardiomyopathy?
Beta-blocker therapy may provide a dose-dependent survival benefit in patients with obstructive hypertrophic cardiomyopathy.
In population-based HOCM cohorts heart failure is a dominant cause of death and on multivariate analysis beta-blocker therapy was associated with a dose-dependent cardioprotective effect on total, disease-related as well as heart failure-related mortality.
Javidgonbadi et al. (Sat,) studied this question.